Table 1.
Baseline patient data (n = 82)
| Clinical variable | HIPEC (n = 37) | Non-HIPEC (n = 45) | P |
|---|---|---|---|
| Sex, n (%) | |||
| Male | 21 (56.8) | 27 (60.0) | 0.767 |
| Female | 16 (43.2) | 18 (40.0) | |
| Age (years, mean±SD) | 63.6±7.0 | 61.6±7.8 | 0.283 |
| KPS, n (%) | |||
| ≥70 | 33 (91.9) | 39 (86.7) | 0.724 |
| 60 | 3 (8.1) | 6 (13.3) | |
| PCI, (scores, mean±SD) | 12.86±6.19 | 13.09±7.45 | 0.884 |
| PCI, n (%) | |||
| <20 | 29 (78.4) | 34 (75.6) | 0.763 |
| ≥20 | 8 (21.6) | 11 (24.4) | |
| Degree of ascites, n (%) | |||
| Small or no | 22 (59.5) | 29 (64.4) | 0.751 |
| Moderate | 10 (27.0) | 9 (20.0) | |
| Large | 5 (13.5) | 7 (15.6) | |
| Distant metastasis, n (%) | |||
| Yes | 7 (18.9) | 9 (20.0) | 0.902 |
| No | 30 (81.1) | 36 (80.0) | |
| Site of primary, n (%) | |||
| Right colon | 9 (24.3) | 7 (15.6) | 0.713 |
| Left colon | 17 (45.9) | 24 (53.3) | |
| Sigmoid | 6 (16.2) | 6 (13.3) | |
| Rectum | 5 (13.5) | 8 (17.8) | |
| Targeted drug, n (%) | |||
| Yes | 12 (32.4) | 9 (20.0) | 0.199 |
| No | 25 (67.6) | 36 (80.0) | |
HIPEC hyperthermic intraperitoneal chemotherapy, KPS Karnofsky performance scale, PCI peritoneal cancer index